Journal
ARCHIVES OF NEUROLOGY
Volume 64, Issue 7, Pages 1007-1013Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archneur.64.7.1007
Keywords
-
Categories
Funding
- NIA NIH HHS [R01 AG014673-08, R01 AG014673, P01 AG007232, AG014673, P01 AG007232-20] Funding Source: Medline
- NICHD NIH HHS [HD35897, HD37425, R01 HD037425-05, P01 HD035897-21, U54 HD079123, R01 HD037425, P01 HD035897] Funding Source: Medline
Ask authors/readers for more resources
Background: Deposition of the beta-amyloid peptide A beta(42) is thought to be an important initial step in the pathogenesis of Alzheimer disease ( AD). Individuals with Down syndrome have increased levels of beta-amyloid peptides and an increased risk for AD. Objective: To examine the relation of plasma levels of A beta(42) and A beta(40) to the risk of dementia in nondemented participants and all-cause mortality in adults with Down syndrome. Design: Prospective, community-based longitudinal cohort study. Setting: State and voluntary service providers in New York State. Participants: Adults with Down syndrome ( N=204). Main Outcome Measure: Plasma A beta(42) and A beta(40) levels were measured at initial examination. Participants were assessed for cognitive and functional abilities, behavioral/psychiatric conditions, and health and vital status at 14- to 18-month intervals for 4 cycles of data collection. Results: Among participants who were nondemented at baseline, those in the middle and highest tertiles of plasma A beta(42) levels were more than 2 times as likely to develop AD as those in the lowest tertile. Compared with participants without AD, participants with prevalent AD had higher levels of plasma A beta(42) but not A beta(40). Among all participants, those in the highest tertile of plasma A beta(42) level at baseline were more than twice as likely to die during the study period as those in the lowest tertile, whereas there was no difference in risk of death between those in the middle and lowest tertiles of plasma A beta(42) level. Conclusion: Elevations in plasma A beta(42) peptide levels are associated with earlier onset of AD and increased risk of death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available